EC
BPMC

EcoR1 Capital’s Blueprint Medicines BPMC Stock Holding History

EcoR1 Capital’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,798,300
Closed -$114M – 52
2023
Q2 		$114M Buy
+1,798,300
New +$97.8M 2.78% 12
2020
Q2 		– Sell
-13,946
Closed -$816K – 51
2020
Q1 		$816K Buy
+13,946
New +$897K 0.09% 47

Other funds holding BPMC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

EcoR1 Capital's BPMC Position: Q3 2023 in Review

EcoR1 Capital sold out of Blueprint Medicines (BPMC) in Q3 2023, closing a stake of 1,798,300 shares — an estimated $114M sold.

EcoR1 Capital first reported a position in BPMC in Q1 2020 and held it in 2 quarters. The position peaked at $114M in Q2 2023. 220 funds tracked by Wall St. Rank hold BPMC as of Q3 2023.

  • EcoR1 Capital reported no remaining Blueprint Medicines position as of Q3 2023 after selling out during the quarter.
  • EcoR1 Capital sold 1,798,300 Blueprint Medicines shares in Q3 2023, an estimated $114M.
  • EcoR1 Capital first reported a position in Blueprint Medicines in Q1 2020 and held it in 2 quarters.
  • EcoR1 Capital's Blueprint Medicines position peaked at $114M in Q2 2023.
  • 220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2023.

Based on EcoR1 Capital's 13F filing for Q3 2023, filed 14 Nov 2023.